Uncategorized

Argenx jumps on Phase 3 data for blockbuster Vyvgart

Published

on

The latest results give investors confidence in the drug’s ability to be approved in another indication for which there are no approved treatments. 

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version